![Metalyse Banner](/products/metalyse/sites/default/files/2024-02/Metalyse_Banner.jpg)
Metalyse®
Metalyse® (tenecteplase) is indicated for the thrombolytic treatment of acute myocardial infarction (AMI). Metalyse® (tenecteplase) 25mg is indicated in adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.1
References
-
Metalyse® European Summary of Product Characteristics.